Reevaluation of equivocal HER2 status detected by immunohistochemistry according to the 2019 guidelines for HER2 detection
10.3760/cma.j.cn112151-20200214-00098
- VernacularTitle:运用《乳腺癌HER2检测指南（2019版）》对免疫组织化学检测HER2不确定表达状态的再评估
- Author:
Weiming XU
1
;
Lingna ZHANG
;
Haili JIN
;
Jingjing ZHOU
;
Ziyi WANG
;
Shouxiang WENG
;
Yujing LI
;
Pin ZHOU
;
Meifu GAN
Author Information
1. 浙江省台州医院病理科 317000
- Keywords:
Breast neoplasms;
Genes, erbB-2;
In situ hybridization, fluorescence;
Immunohistochemistry
- From:
Chinese Journal of Pathology
2020;49(11):1152-1157
- CountryChina
- Language:Chinese
-
Abstract:
O bjective To understand the effects and clinical significance of the 2019 guidelines for the human epidermal growth factor receptor 2 (HER2) detection. Methods:According to the 2014 guidelines, 548 cases of invasive breast cancer with equivocal HER2 (2+) detected by immunohistochemistry (IHC) in Taizhou Enze Medical Center, Zhejiang Province, China from 2013 to 2019 were selected. The results of IHC and HER2/CEPl7 double-probe were reevaluated and divided into groups according to the 2019 guidelines for the comparative analysis.Results:Among the 548 IHC HER2 (2+) invasive breast cancers, the number of positive, equivocal and negative cases for HER2 were 96 (17.52%), 81 (14.78%) and 371 (67.70%), respectively, according to the 2014 guidelines. However, according to the 2019 guidelines, 10 cases (1.82%) were reclassified as IHC 1+, 2 cases in the group 2 were reclassified as negative, and all the originally equivocal cases in group 4 were reclassified as negative. Finally, the total number of positive and negative cases for HER2 were 94 (17.15%) and 454 (82.85%), respectively.Conclusions:After applying the 2019 guidelines, the number of IHC 2+ cases decreases, and the positive rate for HER2 also decreases slightly due to the reevaluation change in groups 2 and 4, leading to reclassification of the cases that were deemed equivocal according to the 2014 guidelines. In general, the new 2019 guidelines are more reasonable and easier to use.
